Table 3 Symptom outcome

From: Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)

Baseline symptoms

N (%)

Outcome after 1 month

Better (%)

Stable (%)

Worse (%)

Total patients

40 (100)

17.5

42.5

40.0

Total with symptoms

20 (50)

35.0

25.0

40.0

Dyspnea

7 (17.5)

28.6

28.6

42.8

Asthenia

6 (15.0)

16.7

50.0

33.3

Emoftoe

2 (5.0)

100

0

0

Bone pain

5 (12.5)

20.0

20.0

60.0

Cough

2 (5.0)

100

0

0

Back to article page